Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

Scope

• Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
• Market forecasts for the seasonal influenza vaccines from 2010 to 2017
• Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
• Key drivers and restraints that have created significant impact on the market.
• Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
• Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
• Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2011 in the seasonal influenza vaccine market.

Request a Sample for or Inquire before buying the report @ 

http://www.reportsnreports.com/reports/144082-seasonal-influenza-vaccine-market-in-asia-pacific-region-cell-culture-technology-based-vaccines-to-revolutionize-the-market-by-faster-production-and-high-initial-purity.html

Major points covered in Table of Contents of this report include

Executive Summary
Seasonal Influenza Vaccine Market in Asia-Pacific Region – Introduction
Seasonal Influenza Vaccine Market in Asia-Pacific Region – Market Overview

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Geographical Landscape

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Drivers and Restraints

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Regulatory Landscape

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Pipeline Analysis

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Competitive Landscape

Seasonal Influenza Vaccine Market in Asia-Pacific Region – M&A Landscape

Seasonal Influenza Vaccine Market in Asia-Pacific Region – Appendix

List of Tables

List of Figures

Explore Comprehensive list of more than 127 Tables & Figures available in the report Seasonal Influenza Vaccine Market in Asia-Pacific Region – Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity

Report Details:

Published: December 2011
No. of Pages: 156
Price: Single User License – US$3500        Corporate User License – US$10500